Literature DB >> 3110213

Synergism of platelet-aggregating agents. Role of elevation of cytoplasmic calcium.

J A Ware, M Smith, E W Salzman.   

Abstract

When a pair of platelet agonists, each in subthreshold concentration, is added together or in sequence to a platelet suspension, the platelet response is enhanced. Addition of two agonists to platelets loaded with aequorin also enhanced the observed rise in cytoplasmic ionized calcium ([Ca2+]i) in response to the second agonist if the agonists were added within 20 s of each other. Enhancement of aggregation and secretion required that an increase in [Ca2+]i (as indicated by aequorin but not necessarily indo-1) followed the first agonist, but not that the [Ca2+]i remain elevated until addition of the second agonist. Enhancement was not prevented by aspirin, ADP scavengers, or chelators of extracellular Ca2+. We conclude that a rise in [Ca2+]i induced by a first agonist "primes" platelets for an augmented functional response to a second agonist, which is not, however, determined by the [Ca2+]i at the time of addition of the second agonist.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3110213      PMCID: PMC442228          DOI: 10.1172/JCI113058

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  14 in total

1.  Platelet aggregation and release: effects of low concentrations of thrombin or collagen.

Authors:  M A Packham; M A Guccione; P L Chang; J F Mustard
Journal:  Am J Physiol       Date:  1973-07

2.  Platelet activation by circulating levels of hormones: a possible link in coronary heart disease.

Authors:  N G Ardlie; H A Cameron; J Garrett
Journal:  Thromb Res       Date:  1984-11-15       Impact factor: 3.944

3.  Positive interaction between agonists in the aggregation response of human blood platelets: interation between ADP, adrenaline and vasopressin.

Authors:  J A Grant; M C Scrutton
Journal:  Br J Haematol       Date:  1980-01       Impact factor: 6.998

4.  Synergism between thrombin and epinephrine in human platelets: different dose-response relationships for aggregation and dense granule secretion.

Authors:  V M Steen; H Holmsen
Journal:  Thromb Haemost       Date:  1985-10-30       Impact factor: 5.249

5.  Synergistic responses and receptor occupancy in rabbit blood platelets.

Authors:  T J Hallam; M C Scrutton; R B Wallis
Journal:  Thromb Res       Date:  1982-08-15       Impact factor: 3.944

6.  Sub-aggregatory doses of catecholamines prevent prostacyclin-induced inhibition of platelet aggregation.

Authors:  P M Buttrick; C A Forscher; I I Sussman; H S Mueller
Journal:  Am Heart J       Date:  1985-06       Impact factor: 4.749

7.  Influence of epinephrine on the aggregation response of aspirin-treated platelets.

Authors:  G H Rao; G J Johnson; J G White
Journal:  Prostaglandins Med       Date:  1980-07

8.  Concurrent measurement of platelet ionized calcium concentration and aggregation: studies with the lumiaggregometer.

Authors:  P C Johnson; J A Ware; E W Salzman
Journal:  Thromb Res       Date:  1985-11-15       Impact factor: 3.944

9.  The interrelationship between thromboxane biosynthesis, aggregation and 5-hydroxytryptamine secretion in human platelets in vitro.

Authors:  L C Best; T K Holland; P B Jones; R G Russell
Journal:  Thromb Haemost       Date:  1980-02-29       Impact factor: 5.249

10.  Measurement of ionized calcium in blood platelets with the photoprotein aequorin. Comparison with Quin 2.

Authors:  P C Johnson; J A Ware; P B Cliveden; M Smith; A M Dvorak; E W Salzman
Journal:  J Biol Chem       Date:  1985-02-25       Impact factor: 5.157

View more
  10 in total

1.  Is thrombolysis alone the best therapy for acute myocardial infarction? Current status and emerging strategies.

Authors:  P Golino; J T Willerson
Journal:  Tex Heart Inst J       Date:  1991

2.  Investigation of the role of calpain as a stimulus-response mediator in human platelets using new synthetic inhibitors.

Authors:  J Anagli; J Hagmann; E Shaw
Journal:  Biochem J       Date:  1991-03-01       Impact factor: 3.857

3.  Historical perspective on ADP-induced platelet activation.

Authors:  Marian A Packham; Margaret L Rand
Journal:  Purinergic Signal       Date:  2011-04-02       Impact factor: 3.765

4.  Synergism between thrombin and adrenaline (epinephrine) in human platelets. Marked potentiation of inositol phospholipid metabolism.

Authors:  V M Steen; O B Tysnes; H Holmsen
Journal:  Biochem J       Date:  1988-07-15       Impact factor: 3.857

5.  The potentiation of adrenaline-induced in vitro platelet aggregation by ADP, collagen and serotonin and its inhibition by naftopidil and doxazosin in normal human subjects.

Authors:  N A Alarayyed; B R Graham; B N Prichard; C C Smith
Journal:  Br J Clin Pharmacol       Date:  1995-04       Impact factor: 4.335

6.  Effect of encainide, ODE, MODE, and flecainide on ADP/5-HT induced platelet aggregation and in the anesthetized dog coronary artery stenosis-occlusion model of intravascular thrombosis.

Authors:  J S Fleming; J O Buchanan; F D Yocca; L G Iben; M J Antonaccio
Journal:  Cardiovasc Drugs Ther       Date:  1991-08       Impact factor: 3.727

7.  The influence of platelet activating factor on the effects of platelet agonists and antiplatelet agents in vitro.

Authors:  Friederike K Keating; David J Schneider
Journal:  J Thromb Thrombolysis       Date:  2008-06-25       Impact factor: 2.300

8.  Modelling thrombosis using dissipative particle dynamics method.

Authors:  N Filipovic; M Kojic; A Tsuda
Journal:  Philos Trans A Math Phys Eng Sci       Date:  2008-09-28       Impact factor: 4.226

9.  Treadmill exercise promotes cyclic alterations in coronary blood flow in dogs with coronary artery stenoses and endothelial injury.

Authors:  J F Eidt; J Ashton; P Golino; J McNatt; L M Buja; J T Willerson
Journal:  J Clin Invest       Date:  1989-08       Impact factor: 14.808

Review 10.  Adenosine-associated delivery systems.

Authors:  Mehdi Kazemzadeh-Narbat; Nasim Annabi; Ali Tamayol; Rahmi Oklu; Amyl Ghanem; Ali Khademhosseini
Journal:  J Drug Target       Date:  2015       Impact factor: 5.121

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.